Total revenue of $989 million for the first quarter and $4,652 million on a TTM(1) basis. Rental Segment(2) revenue of $764 million for the first quarter, an increase of 37% year over year, and on a TTM(1) basis $2,932 million, an increase of 36% year over year. Net loss of $29 million for the first quarter and net income of $58 million on a TTM(1) basis. Adjusted net loss(4) for the first quarter of $12 million and adjusted net income(4) of $75 million on a TTM(1) basis. Adjusted Core EBITDA(3) of $399 million for the first quarter and $1,776 million on a TTM(1) basis. Mature rental locations(2)(6) adjusted EBITDA margins were 55% on a TTM(1) basis. 407 locations(6) with 22 new locations opened during the first quarter.COLUMBIA, Mo., May 13, 2026 (GLOBE NEWSWIRE) — EquipmentShare.com Inc (Nasdaq: EQPT) (“EquipmentShare” or...

-Third Quarter Revenue Increased 65% Year-over-Year to $4.2 Million- -Fiscal Year-to-Date Revenue Increased 67% to $13.5 Million- -Legacy De-SPAC Liabilities Reduced by More Than 95% Since Fiscal Year-End 2024- -Stockholders’ Equity Improved to $22.3 Million from a $(6.8) Million Deficit at Fiscal Year-End– -Stock Locate and Securities Lending Revenue Reached $3.0 Million Fiscal Year-to-Date- -Five Correspondent Relationships Signed or Actively Onboarding- -Earnings Conference Call Scheduled for Thursday, May 14, 2026, at 8:30 AM ET- TAMPA, Fla., May 13, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (“AtlasClear” or the “Company”) (NYSE American: ATCH), a technology-enabled financial services platform modernizing trading, clearing, settlement, and banking infrastructure, today announced financial...

Conference call today, May 13, 2026, at 4:30 PM ET SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. “The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community,” commented Al Luderer, Ph.D., chairman and interim chief executive officer of Bionano. “The evidence base supporting OGM continues to expand across hematologic malignancies, constitutional genetics, and cell and gene therapy applications, and we are seeing global broad-based adoption at leading institutions. We remain convinced that OGM is on a clear and accelerating path to becoming the...

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership, while advancing scale-up and commercialization activities for additional recombinant products, including transferrin Signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic’s recombinant products, with initial product quantities completed for shipment to support commercialization through IBT’s global...

Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027 ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “I’m very pleased with the progress our team made in the first quarter....

First Quarter 2026 Revenues of $4.2 Million; SEA-IX™ Nuclear-Grade Ion Exchange Resin Line Launched with Approximately $1 Million in Initial Orders; $78 Million Final Judgment Collection Efforts Underway CORSICANA, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today reported financial results for the first quarter ended March 31, 2026. Key First Quarter 2026 & Subsequent Operational HighlightsSuccessfully uplisted to the NYSE American in February 2026 with a concurrent public offering raising aggregate gross proceeds of approximately $16.4 million, significantly strengthening the Company’s balance sheet and expanding its investor base. Initiated collection...

Net Loss Improves by $3.9 Million in Q1’26 vs Q1’25 Underscoring Continued Operational and Financial Momentum Gross Margin increased 480 basis points in Q1’26 vs Q1’25 Reduced Total Debt by $1.1M and Net Debt by $5.8M During Q1’26 CHICO, Calif., May 13, 2026 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU) today reported financial results for the first quarter ended March 29, 2026 and reaffirmed its financial outlook for the fiscal year ending January 3, 2027. Crystal Landsem, CEO of Lulus, said: “Our first quarter results reflect continued progress in strengthening the foundation of the business, even as we took deliberate strategic actions to re-position our assortment as we move into our peak selling periods. During the quarter, we prioritized higher quality demand and disciplined...

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Initiated efforts for the submission of a modular post-marketing application (PMA) Webcast today at 4:30 pm Eastern Time DENVER, May 13, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended March 31, 2026, and provided business updates on key initiatives. “Our QUELIMMUNE customer base continues to grow with a groundswell of enthusiasm among...

Enovix Begins Commercial Production of Silicon-Anode Smart Eyewear Battery Enovix Advances Toward Smartphone Qualification Completion FREMONT, Calif., May 13, 2026 (GLOBE NEWSWIRE) — Enovix Corporation (Nasdaq: ENVX) (“Enovix”), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, today reported financial results for the first quarter of 2026. The Company will host a live webcast at 5:00 PM ET / 2:00 PM PT to discuss the results and provide a business update. To register for the webcast, please visit: https://enovix-q1-2026.open-exchange.net/. Commercialization Progress“Smartphones remain our priority as we advance toward completing qualification with our lead customer and prepare for commercial production for the most demanding market in consumer electronics,” said...

         PRESS RELEASE AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIODFinancial and corporate positionOperating loss of €3.8 million as of 31 December 2025, down 38% compared with the 2025 financial year (excluding non-recurring items) Cash position of €10.2 million as of 31 December 2025, plus €3.2 million from the private placement carried out in April 2026 Final agreement on the renegotiation of the repayment terms of its loans with all financial creditorsClinical development: focus of resources on Phase 3 of masitinib in ALS and Phase 1 of AB8939 in acute myeloid leukaemia (AML)Paris, 13 May 2025, 7pm CET AB Science SA (Euronext – FR0010557264 – AB) today announces its annual financial results as of 31 December 2025 and provides an update on its activities....